NASDAQ: ASPEAspen Neuroscience Inc Stock
$13.04-1.85 (-12.42%)
Updated Nov 2, 2026
ASPE Price
$13.04
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$11.60
52 Week High
$14.90
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.44
Operating Cash Flow
N/A
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ASPE Overview
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquartered in San Diego, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ASPE's potential to beat the market
- ASPE doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ASPE
RankedUnranked of 452
RankedUnranked of 452
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $961.26 | A | |
| $10.18 | A | |
| $361.27 | A |
Be the first to know about important ASPE news, forecast changes, insider trades & much more!
ASPE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ASPE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ASPE's short-term assets ($74.60M) exceed its short-term liabilities ($16.35M)
Short-term Liabilities Financials
ASPE's long-term liabilities ($345.00M) exceed its short-term assets ($74.60M)
Long-term Liabilities Financials
ASPE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more ASPE due diligence checks available for Premium users.
Valuation
ASPE's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$110.3M
Liabilities
$361.3M
Debt to equity
-1.44
ASPE's short-term assets ($74.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ASPE's long-term liabilities ($345.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ASPE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ASPE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
Aspen Neuroscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.